HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $54
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on UroGen Pharma and raises the price target from $23 to $54.
August 01, 2023 | 10:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma's price target has been raised from $23 to $54 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for UroGen Pharma. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100